Literature DB >> 2637670

Ileocolonoscopy in seronegative spondylarthropathy.

M De Vos1, C Cuvelier, H Mielants, E Veys, F Barbier, A Elewaut.   

Abstract

A prospective endoscopic and histologic study of terminal ileum and colorectum in 211 patients with seronegative spondylarthropathy revealed macroscopic inflammatory lesions varying from erythema to superficial erosions in 30% of the patients and microscopic inflammation in 61%. Two types of inflammation were observed: an acute inflammation resembling an infectious enterocolitis and a chronic inflammation. In idiopathic reactive arthritis both types of inflammation were equally present, whereas chronic inflammation predominated in patients with ankylosing spondylitis. In 32% of patients with chronic inflammation, the lesions particularly resembled early Crohn's disease. Repeat ileocolonscopy on 19 patients demonstrated a parallel evolution of joint symptoms and histologic lesions. All patients with acute inflammation went into clinical and histologic remission, whereas lesions persisted in patients with Crohn-like inflammation. In patients with chronic inflammation, remission and persistence were observed equally. This study identified a group of patients with seronegative spondylarthropathy which, even in the absence of gastrointestinal symptoms, showed evidence of gut inflammation, probably inducing an increased gut permeability with transgression of the oral tolerance and absorption of provocative antigens into the circulation. It is also possible that both diseases reflect a common underlying process.

Entities:  

Mesh:

Year:  1989        PMID: 2637670     DOI: 10.1016/0016-5085(89)91557-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Non-steroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: a report of two cases.

Authors:  I W Fellows; J M Clarke; P F Roberts
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

4.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

5.  Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex.

Authors:  P Demetter; D Baeten; F De Keyser; M De Vos; N Van Damme; G Verbruggen; S Vermeulen; M Mareel; D Elewaut; H Mielants; E M Veys; C A Cuvelier
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

6.  Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug effect?

Authors:  A J Morris; C W Howden; C Robertson; A Duncan; H Torley; R D Sturrock; R I Russell
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

7.  Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies.

Authors:  L Altomonte; A Zoli; A Veneziani; L Mirone; G Santacesaria; C Chiarelli; F Federico; G Massi; M Magaro
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 8.  Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis.

Authors:  M L Stoll
Journal:  Clin Exp Rheumatol       Date:  2011-04-19       Impact factor: 4.473

9.  Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy.

Authors:  C Cuvelier; H Mielants; M De Vos; E Veys; H Roels
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

10.  NSAIDs: the emperor's new dogma?

Authors:  I Bjarnason; K Takeuchi; R Simpson
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.